Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW27011 in Locally Advanced and/or Metastatic Solid Tumors
NCT06792435Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ASP546C in solid tumor, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma (PDAC), ovarian cancer, sponsored by Astellas Pharma. Started Jul 2023; status: active, not recruiting.
02
Drugs
ASP546C
03
Conditions
solid tumorgastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic adenocarcinoma (PDAC)ovarian cancer
Beyond the preview
Go deeper on NCT06792435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792435.